Editorial
doi: 10.1086/651143.
HIV neutralizing antibodies: clinical correlates and implications for vaccines
- PMID: 20170372
- PMCID: PMC2832095
- DOI: 10.1086/651143
Item in Clipboard
Editorial
HIV neutralizing antibodies: clinical correlates and implications for vaccines
J Infect Dis.
.
No abstract available
Conflict of interest statement
The author declares no conflict of interests.
Comment on
-
Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression.J Infect Dis. 2010 Apr 1;201(7):1045-53. doi: 10.1086/651144. J Infect Dis. 2010. PMID: 20170371
Similar articles
-
HIV Vaccines: One Step Closer.Trends Mol Med. 2017 Jan;23(1):1-3. doi: 10.1016/j.molmed.2016.10.006. Epub 2016 Nov 23. Trends Mol Med. 2017. PMID: 27889424
-
Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning.Nat Rev Immunol. 2013 Sep;13(9):693-701. doi: 10.1038/nri3516. Nat Rev Immunol. 2013. PMID: 23969737 Review.
-
HIV vaccine development--improving on natural immunity.N Engl J Med. 2011 Sep 8;365(10):873-5. doi: 10.1056/NEJMp1107621. N Engl J Med. 2011. PMID: 21899447 No abstract available.
-
Tiny steps towards an HIV vaccine.Nature. 2010 Jul 15;466(7304):S8. doi: 10.1038/nature09238. Nature. 2010. PMID: 20631706 No abstract available.
-
Recent strategies targeting HIV glycans in vaccine design.Nat Chem Biol. 2014 Dec;10(12):990-9. doi: 10.1038/nchembio.1685. Nat Chem Biol. 2014. PMID: 25393493 Free PMC article. Review.
Cited by
-
Three families of CD4-induced antibodies are associated with the capacity of plasma from people living with HIV to mediate ADCC in the presence of CD4-mimetics.J Virol. 2024 Oct 22;98(10):e0096024. doi: 10.1128/jvi.00960-24. Epub 2024 Sep 4. J Virol. 2024. PMID: 39230306 Free PMC article.
-
High-Frequency, Functional HIV-Specific T-Follicular Helper and Regulatory Cells Are Present Within Germinal Centers in Children but Not Adults.Front Immunol. 2018 Sep 12;9:1975. doi: 10.3389/fimmu.2018.01975. eCollection 2018. Front Immunol. 2018. PMID: 30258437 Free PMC article. Clinical Trial.
-
Functional development of a V3/glycan-specific broadly neutralizing antibody isolated from a case of HIV superinfection.Elife. 2021 Jul 15;10:e68110. doi: 10.7554/eLife.68110. Elife. 2021. PMID: 34263727 Free PMC article.
-
SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise.Microorganisms. 2021 Jun 27;9(7):1389. doi: 10.3390/microorganisms9071389. Microorganisms. 2021. PMID: 34198973 Free PMC article. Review.
-
Activation-induced Markers Detect Vaccine-Specific CD4⁺ T Cell Responses Not Measured by Assays Conventionally Used in Clinical Trials.Vaccines (Basel). 2018 Jul 31;6(3):50. doi: 10.3390/vaccines6030050. Vaccines (Basel). 2018. PMID: 30065162 Free PMC article.
References
-
- Beirnaert E, Nyambi P, Willems B, et al. Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates. J Med Virol. 2000;62:14–24. - PubMed
-
- Graham BS. Clinical trials of HIV vaccines. Annu Rev Med. 2002;53:207–221. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
